Executive Summary

Investment Thesis: Tempest Therapeutics ($TPST) reported a materially smaller-than-expected Q4 loss, signaling improved cost or operational performance, and it has arranged up to $6 million in financing to extend the runway. However, the company remains a microcap biotech with substantial cumulative losses, limited cash, and potential dilution from attached warrants. For investors, this is a binary, catalyst-driven story tied to clinical progress and financing execution.

Current Price: $1.59 | Key Metric: Market Cap $23.3M | Stance: NEUTRAL

Company Overview

Tempest Therapeutics Inc is a small biotechnology company focused on oncology-focused therapeutic candidates, including TPST-2003 which is positioned for a planned U.S. registrational study in 2026. The company operates at the clinical development stage and has limited commercial revenue.

Key Products & Competitive Position

Core Business: Early- to mid-stage clinical development of oncology therapeutics, pursuing registration-enabling studies for selected assets.
Key Products: TPST-2003 (lead asset preparing for potential registrational study), and earlier-stage programs in targeted oncology.
Competitive Moat: Specialist science and clinical data on lead assets. The moat is narrow, driven by clinical differentiation if trials succeed, rather than by scale or recurring revenue.

Recent Developments

Key developments include a Q4 2025 EPS print that materially beat consensus estimates, and a financing announced on March 23, 2026, for up to $6.0 million with warrants exercisable at $2.16 per share. The company also reported interim REDEEM-1 trial data and said it is preparing for a potential U.S. registrational study in 2026 for TPST-2003.

Financial Snapshot

Market Cap$23.3M

P/E RatioN/A

52-Week Range$1.56 - $12.23

Dividend Yield0.0%

EPS (TTM)$-10.40

ROE-310.89%

Revenue & Earnings Trends

Tempest does not report meaningful recurring revenue. Net losses remain the defining feature of the income statement. The company delivered Q4 2025 EPS of $(0.62) per share, which materially beat the consensus estimate of $(3.52). That improvement suggests either lower one-time charges or operating cost reductions versus expectations, but absolute profitability is still far away.

Balance Sheet Highlights

Reported cash (most recent public disclosure) is limited, with third-party data showing roughly $7.5 million in cash on the balance sheet. The announced private placement for up to $6.0 million should extend the runway, but it comes with warrants and will dilute existing shareholders if exercised. Debt levels are modest in absolute terms, but recent data indicate a high debt to equity ratio when measured against the tiny equity base, which raises leverage concerns for a microcap biotech.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: N/A

PEG RatioN/AGrowth-adjusted

EV/EBITDAN/Avs Historical: N/A

P/S RatioN/Avs Peers: N/A

Historical Comparison

TPST traded as high as $12.23 in October 2025, implying substantially higher implied valuations when markets were pricing clinical potential more aggressively. Today, the stock sits close to its 52-week low near $1.56, reflecting a de-risked price that factors in trial and financing risk. Past volatility has been extreme, with two-year total return metrics showing significant drawdown from earlier highs.

Fair Value Estimate

Traditional multiples are not meaningful for a pre-commercial biotech with large negative EPS. A reasonable framework is outcomes-based valuation tied to successful registrational study outcomes and eventual partnering or commercialization. Using a scenario approach, fair value spans a wide range: low-single-digit dollars under failure or prolonged delay scenarios, and multi-dollar to double-digit valuations only if registrational studies succeed and partnerships materialize. This wide range explains divergent analyst views and the strong consensus buy rating despite a depressed market price.

Competitive Landscape

Market Position

Market Share: Negligible from a commercial standpoint | Ranking: Early-stage player in oncology therapeutics

Key Competitors

$VIVDVividion Therapeutics and other small-cap oncology biotechs focused on targeted therapies and clinical-stage pipelines

$XXIIPeer small-cap oncology developers pursuing registration studies

$XYZLarger oncology players with commercial capabilities and broader pipelines

Competitive Advantages

Moat 1: Clinical data on TPST-2003 that supports a registrational pathway if results hold up.
Moat 2: Focused pipeline with a clear development plan, which can be attractive to partners if endpoints are met.
Moat 3: Small corporate structure allows lean operations and potentially faster decision cycles.

Earnings Track Record

Last 4 Quarters: 1 beat / 0 misses (other quarters limited data)

Recent Earnings History

Q4 2025$(0.62) vs $(3.52) estBEAT

Q3 2025N/AN/A

Q2 2025N/AN/A

Q1 2025N/AN/A

Guidance Trend

Management has not issued revenue guidance given the pre-commercial stage. The key forward-looking item is the planned U.S. registrational study for TPST-2003 in 2026, contingent on ongoing trial data. Analysts will be watching management commentary around timeline, cash runway, and partnership opportunities closely in upcoming releases.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 2 Buy: 4 Hold: 1 Sell: 0

Price Targets

Low: $2.00
Mean: $6.00 (+277% upside)
High: $12.00

Recent Analyst Actions

Analysts appear constructive following interim trial data and the Q4 beat. The consensus Strong Buy rating reflects the view that clinical catalysts could re-rate the stock if the registrational path verifies. At the same time, coverage is light at seven analysts, and price targets vary widely as analysts assign different probabilities to clinical success and partnership outcomes.

Recent News & Catalysts

Key Developments

Q4 EPS Beat (3/30/2026): Reported $(0.62) per share versus $(3.52) expected, an 82% positive surprise as reported by Benzinga.
Private Placement (3/23/2026): Up to $6.0M financing announced, including warrants with $2.16 exercise price, which will dilute shareholders if exercised but provides near-term runway.
Clinical Progress: Interim REDEEM-1 trial results and partnership announcements related to TPST-2003 preparation for a planned U.S. registrational study in 2026.

Upcoming Catalysts

Next Earnings: Q1 2026 expected 2026-05-11 After Market | Key Events: Management commentary on cash runway post-placement, updates on REDEEM-1 or registrational study timing, and any partnership activity.

Technical Outlook

Current Price: $1.59 vs 52-Week High: $12.23 (-87% from high)

Trend Analysis

Price action has been decisively downward from the October 2025 peak, and the stock recently touched a 52-week low at $1.56 on March 27, 2026. The significant gap between the high and current price reflects a market repricing after volatility in trial readouts and funding uncertainty. Momentum indicators are likely negative in the near term given recent selling pressure and limited liquidity.

Key Levels

Resistance: $2.16 (warrant exercise strike), $3.50
Support: $1.56, $1.20

Bull vs Bear Case

Bull Case

Catalyst 1: Positive registrational study design and strong interim data for TPST-2003 could attract partners and re-rate the stock.
Catalyst 2: The recent Q4 EPS beat signals improved cost control or reduced one-time charges, which could indicate better operational leverage as programs progress.
Catalyst 3: Financing provides runway to key inflection points and warrants align investor upside if trials succeed, supporting higher valuations on positive outcomes.

Bull Target: $12.00 (+655%)

Bear Case

Risk 1: Clinical failure or delayed registrational study would likely push the stock lower, given the tiny cash buffer and lack of revenue.
Risk 2: The announced private placement and warrants will dilute existing shareholders and may cap upside until warrants expire or convert.
Risk 3: Very low market cap and limited liquidity increase volatility and raise the risk of investor exits driving steep intraday moves.

Bear Target: $0.80 (-50%)

Risks to Consider

Valuation Risk: Traditional valuation metrics are not meaningful due to negative earnings and lack of revenue, producing very wide fair value dispersion.
Competitive Risk: Larger, better-capitalized oncology companies can outspend and out-license smaller players, reducing strategic options for TPST if trials are costly or slow.
Macro Risk: Biotech funding environments can tighten quickly, and microcap issues are sensitive to changes in risk appetite among institutional investors.
Execution Risk: Clinical development is binary. Trial design, enrollment, and data quality are all points where the program can fail, and a failed registrational bid would be materially value destructive.

Bottom Line

Investment Verdict: NEUTRAL

Data suggests the company is running to key clinical and financing milestones, and analysts remain broadly optimistic. At the same time, TPST is a very small, high-volatility biotech with limited cash and meaningful dilution risk. For many investors this will remain a high-risk, high-reward speculative situation tied to clinical outcomes and financing execution.

Action Items for Investors

Long-term investors: Monitor registrational study progress and partnership developments, and watch dilution metrics closely before increasing exposure.
Short-term traders: Expect high intraday volatility around news, earnings, and financing updates; liquidity risk may widen spreads and increase execution risk.
Risk management: Size positions to reflect uncertainty, set clear stop levels, and track cash runway and warrant overhang as key risk signals.

What to Watch This Week

Any trading updates or further details on the private placement and warrant terms.
Pre-earnings commentary or guidance ahead of the Q1 2026 release expected May 11, 2026, and disclosure timing for registrational study plans.
Clinical updates from REDEEM-1 or related TPST-2003 communications that could clarify the registrational pathway.

TPST: Cash Raise and Trial Catalysts